

Diabetic Gastroparesis Market Outlook 2032: FDA Approval, Therapies, Clinical Trials, Companies by DelveInsight

Diabetic Gastroparesis companies are Neurogastrx, Takeda, Theravance Biopharma, Allergan Evoke Pharma, Censa Pharmaceuticals, CinDome, Bird Rock Bio, more.

ALBANY, NEW YORK, UNITED STATES, June 18, 2024 /EINPresswire.com/ -- DelveInsight's "Diabetic Gastroparesis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Diabetic Gastroparesis, historical and


forecasted epidemiology as well as the Diabetic Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Diabetic Gastroparesis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Diabetic Gastroparesis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Diabetic Gastroparesis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Diabetic Gastroparesis market.

Request for a Free Sample Report @ [Diabetic Gastroparesis Market Forecast](#)

Some facts of the Diabetic Gastroparesis Market Report are:

- According to DelveInsight, Diabetic Gastroparesis market size is expected to grow at a decent CAGR by 2032.
- Diabetic Gastroparesis Market Size in the 7MM is expected to reach USD 4331.47 million by 2030.
- Leading Diabetic Gastroparesis companies working in the market are Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, Allergan Evoke Pharma Inc, Theravance Biopharma, Censa Pharmaceuticals, CinDome Pharma, Bird Rock Bio,



and others.

- Key Diabetic Gastroparesis Therapies expected to launch in the market are Relamorelin, CIN-102, Velusetrag, Gimoti, and others.
- According to the DelveInsight's estimates, total prevalent population of Diabetic Gastroparesis in the 7MM expected to rise to 17,859,995 in 2030.
- About 40% of patients with Type 1 Diabetes have gastroparesis as per studies carried out in tertiary care centers while approximately 30% of Type 2 DM cases suffer from DGp.
- Of the emerging therapies, the most anticipated product to get launched is the metoclopramide nasal spray Gimoti (Evoke Pharma). Apart from this, other products include Velusetrag [Theravance Biopharma], TAK 954 (Theravance Biopharma/ Takeda), CNSA-001 (Censa Pharmaceuticals), CIN-102 Cindome Pharmaceuticals and Relamorelin (Allergan). Some of these products have also received Fast track Designation.
- On April 2024, CinDome Pharma, Inc. announced results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis.
- On March 2024, Vanda Pharmaceuticals announced results of VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study To Assess The Efficacy Of Trapidant In Relieving Symptoms Of Gastroparesis.

Diabetic Gastroparesis Overview

Diabetic gastroparesis (DGp) is a term used to describe a serious complication of diabetes that leads to a delay in the emptying of the stomach, causing upper gastrointestinal (GI) symptoms even in the absence of any physical blockage.

Common risk factors for this condition include having diabetes, a history of abdominal or esophageal surgery, advancing age, and the use of alcohol and tobacco. The key symptoms and signs of gastroparesis include feeling full soon after starting a meal, upper abdominal discomfort, nausea, vomiting, ongoing loss of appetite, and a sensation of fullness after eating; these symptoms tend to persist over time with occasional flare-ups.

Patients with Diabetic gastroparesis often experience additional gastric problems, such as gastroesophageal reflux disease, impaired intestinal motility, and fungal and bacterial infections in the GI tract. They may also suffer from macro- and micro-vascular complications related to diabetes. Consequently, effective management of Diabetic gastroparesis often necessitates a collaborative approach involving a team of specialized healthcare professionals.

Learn more about Diabetic Gastroparesis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Diabetic Gastroparesis Market

The Diabetic Gastroparesis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Diabetic Gastroparesis market trends

by analyzing the impact of current Diabetic Gastroparesis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Diabetic Gastroparesis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Diabetic Gastroparesis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Diabetic Gastroparesis market in 7MM is expected to witness a major change in the study period 2019-2032.

Diabetic Gastroparesis Epidemiology

The Diabetic Gastroparesis epidemiology section provides insights into the historical and current Diabetic Gastroparesis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Diabetic Gastroparesis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Diabetic Gastroparesis Epidemiology @ [Diabetic Gastroparesis Market Dynamics and Trends](#)

Diabetic Gastroparesis Drugs Uptake

This section focuses on the uptake rate of the potential Diabetic Gastroparesis drugs recently launched in the Diabetic Gastroparesis market or expected to be launched in 2019-2032. The analysis covers the Diabetic Gastroparesis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Diabetic Gastroparesis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Diabetic Gastroparesis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Diabetic Gastroparesis Pipeline Development Activities

The Diabetic Gastroparesis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Diabetic Gastroparesis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Diabetic Gastroparesis pipeline development activities @ https://www.delveinsight.com/sample-request/diabetic-gastroparesis-market-size?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Diabetic Gastroparesis Therapeutics Assessment

Major key companies are working proactively in the Diabetic Gastroparesis Therapeutics market to develop novel therapies which will drive the Diabetic Gastroparesis treatment markets in the upcoming years are Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, Allergan Evoke Pharma Inc, Theravance Biopharma, Censa Pharmaceuticals, CinDome Pharma, Bird Rock Bio, and others.

Learn more about the emerging Diabetic Gastroparesis therapies & key companies @ [Diabetic Gastroparesis FDA Approvals and Clinical Trials](#)

Diabetic Gastroparesis Report Key Insights

1. Diabetic Gastroparesis Patient Population
2. Diabetic Gastroparesis Market Size and Trends
3. Key Cross Competition in the Diabetic Gastroparesis Market
4. Diabetic Gastroparesis Market Dynamics (Key Drivers and Barriers)
5. Diabetic Gastroparesis Market Opportunities
6. Diabetic Gastroparesis Therapeutic Approaches
7. Diabetic Gastroparesis Pipeline Analysis
8. Diabetic Gastroparesis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Diabetic Gastroparesis Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Diabetic Gastroparesis Competitive Intelligence Analysis
4. Diabetic Gastroparesis Market Overview at a Glance
5. Diabetic Gastroparesis Disease Background and Overview
6. Diabetic Gastroparesis Patient Journey
7. Diabetic Gastroparesis Epidemiology and Patient Population
8. Diabetic Gastroparesis Treatment Algorithm, Current Treatment, and Medical Practices
9. Diabetic Gastroparesis Unmet Needs
10. Key Endpoints of Diabetic Gastroparesis Treatment
11. Diabetic Gastroparesis Marketed Products
12. Diabetic Gastroparesis Emerging Therapies
13. Diabetic Gastroparesis Seven Major Market Analysis
14. Attribute Analysis
15. Diabetic Gastroparesis Market Outlook (7 major markets)
16. Diabetic Gastroparesis Access and Reimbursement Overview
17. KOL Views on the Diabetic Gastroparesis Market
18. Diabetic Gastroparesis Market Drivers
19. Diabetic Gastroparesis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Ankit Nigam

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/720903633>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.